General Electric Company

Oxford University Innovation Limited

Oxford Cancer Biomarkers Ltd

Celleron Therapeutics Limited

David Kerr

Matthew David Kelly

Brion Daryl Sarachan

Christopher Reynolds Hammond

John Robert Maddison

Havard E Danielsen

John Michael Brady

Nicholas La Thangue

Dan Rosmarin

Rachel Susannah Midgley

Claire Palles

Mark Robert Austin

Ian Tomlinson

Simon Cook

The present invention relates to N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, for use as an anti-inflammatory agent, in particular for use in the treatment of immune checkpoint inhibitor-induced colitis.

Treatment of inflammatory disease

The invention provides an assay useful in predicting risk of 5-fluorouracil (FU) toxicity in a subject. The subject may be screened for the presence of at least one TYMS polymorphism and/or at least one DPYD polymorphism. Suitable TYMS and DPYD polymorphisms are provided. The presence of one or more of the polymorphisms indicates an increased risk of developing FU toxicity; a negative result may indicate a decreased risk of developing FU toxicity.

Method of determining risk of 5-fluorouracil toxicity

Quantitative analysis of a tissue sample includes carrying out a ploidy measurement on a plurality of nuclei of the sample to determine the ploidy type of a sample and also carrying out a stroma measurement on a section to determine the stroma type of a sample. The ploidy type, e.g. diploid or non-diploid, and the stroma type, high or low stroma, give an improved patient survival estimate than the ploidy type alone.

Tissue sample analysis technique

A method and system are provided for facilitating decision making, such as in a clinical setting. In accordance with this technique, a set of encoded guidelines are executed to identify information that may be used to generate patient management options. The information is acquired, if available. Based on the encoded guidelines and the acquired information, a set of patient management options are generated and provided to one or more reviewers for review and selection of a patient management option.

Method and system for supporting clinical decision-making

Growing community of inventors

Oxford, United Kingdom

David Kerr